Prime Medicine, Inc. (PRME)
$3.59-$0.05 (-1.37%) Today
Robert Nelsen - DirectorRobert Nelsen - DirectorPrime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 7 | 525,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
30 Form 4 filings on record, the earliest from Oct 10, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David P. Schenkein - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Jeffrey D. Marrazzo - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Robert Nelsen - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
 Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
 Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
 Thomas Cahill - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
 Svetlana Ni Makhni - Officer | Grant or award | Stock Option (right to buy) | 800,000 | $0.00 | - | |
| Allan Reine - Officer | Grant or award | Stock Option (right to buy) | 1,300,000 | $0.00 | - | |
| Ann L. Lee - Officer | Grant or award | Stock Option (right to buy) | 375,000 | $0.00 | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 140,000 | $0.00 | - | |
| GV 2021 GP, L.L.C. | Open-market purchase | Common Stock | 1,500,000 | $3.30 | $4.95M | |
| Robert Nelsen - Director | Open-market purchase | Common Stock | 3,030,300 | $3.30 | $10.00M | |
| ARCH Venture Partners XII, LLC - 10% Owner | Open-market purchase | Common Stock | 3,030,300 | $3.30 | $10.00M | |
| ARCH Venture Partners X, LLC - 10% Owner | Open-market purchase | Common Stock | 3,030,300 | $3.30 | $10.00M | |
| Kaye I. Foster-Cheek - Director | Derivative | Stock Option (right to buy) | 13,510 | - | - | |
| Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 13,510 | - | - | |
| Kaye I. Foster-Cheek - Director | Derivative | Stock Option (right to buy) | 9,006 | - | - | |
| Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 9,006 | - | - | |
| Kaye I. Foster-Cheek - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| Kaye I. Foster-Cheek - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Michael Aaron Kelly - Director | Derivative | Stock Option (right to buy) | 13,510 | - | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 13,510 | - | - | |
| Michael Aaron Kelly - Director | Derivative | Stock Option (right to buy) | 9,006 | - | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 9,006 | - | - | |
| Michael Aaron Kelly - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| Michael Aaron Kelly - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Ann L. Lee - Officer | Derivative | Stock Option (right to buy) | 180,995 | - | - | |
| Ann L. Lee - Officer | Grant or award | Stock Option (right to buy) | 180,995 | - | - | |
| Ann L. Lee - Officer | Derivative | Stock Option (right to buy) | 180,995 | - | - | |
| Ann L. Lee - Officer | Grant or award | Stock Option (right to buy) | 180,995 | - | - | |
| Allan Reine - Officer | Derivative | Stock Option (right to buy) | 850,000 | - | - | |
| Allan Reine - Officer | Grant or award | Stock Option (right to buy) | 850,000 | - | - | |
| Carman Alenson - Officer | Derivative | Stock Option (right to buy) | 16,083 | - | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 16,083 | - | - | |
| Carman Alenson - Officer | Derivative | Stock Option (right to buy) | 90,498 | - | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 90,498 | - | - | |
| Carman Alenson - Officer | Derivative | Stock Option (right to buy) | 6,254 | - | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 6,254 | - | - | |
| Carman Alenson - Officer | Derivative | Stock Option (right to buy) | 90,498 | - | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 90,498 | - | - | |
| Jeffrey D. Marrazzo - Director | Derivative | Stock Option (right to buy) | 92,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Grant or award | Stock Option (right to buy) | 92,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Derivative | Stock Option (right to buy) | 250,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Grant or award | Stock Option (right to buy) | 250,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| David P. Schenkein - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| David P. Schenkein - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| David P. Schenkein - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| David P. Schenkein - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Wendy Chung - Director | Derivative | Stock Option (right to buy) | 13,510 | - | - | |
| Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 13,510 | - | - | |
| Wendy Chung - Director | Derivative | Stock Option (right to buy) | 9,006 | - | - | |
| Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 9,006 | - | - | |
| Wendy Chung - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| Wendy Chung - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Thomas Cahill - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| Thomas Cahill - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| Thomas Cahill - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Thomas Cahill - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| David R. Liu - 10% Owner | Open-market purchase | Common Stock | 21,000 | $2.52 | $53K | |
| Robert Nelsen - Director | Grant or award | Stock Option (right to buy) | 55,000 | $0.00 | - | |
| Keith Michael Gottesdiener - Officer | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Richard Brudnick - Officer | Grant or award | Stock Option (right to buy) | 19,300 | $0.00 | - | |
| Allan Reine - Officer | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Keith Michael Gottesdiener - Officer | Gift | Common Stock | 226,925 | $0.00 | - | |
| Keith Michael Gottesdiener - Officer | Gift | Common Stock | 226,925 | $0.00 | - |
Prime Medicine, Inc. (PRME) had 7 insider filings in the last 90 days, with the most recent on 2026-06-08. The full record for PRME runs to 30 Form 4 filings, the earliest from 2024-10-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of PRME were filed in the last 90 days. 5 purchases are on record for this company.
No insider sales of PRME were filed in the last 90 days.
This page tracks PRME Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PRME to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
